Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | World Journal of Surgical Oncology

Figure 2

From: Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity

Figure 2

Kaplan-Meier estimates of failure-free survival and overall survival of patients with locally advanced rectal cancer undergoing neoadjuvant bevacizumab and chemoradiotherapy. The solid line, dashed line, and dotted line represent all 18 patients, 6 patients in the supine box group, and 12 patients in the prone volumetric modulated arc therapy group, respectively.

Back to article page